Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04996836 | Breast Cancer, Omics, and Precision Medicine(BR(E)2ASTOME) | unknown | Phase 2 | 200 | University of Campania Luigi VanvitelliOTHER | 0 | Aug 13, 2021 | clinicaltrials |
| NCT05004142 | Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin | unknown | Phase 2 | 70 | Ahon Pharmaceutical Co., Ltd.OTHER | 1 | Aug 13, 2021 |
| NCT04999540 | Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer | unknown | Phase 2 | 73 | Guangdong Women and Children HospitalOTHER | 0 | Aug 11, 2021 | clinicaltrials |
| NCT02917005 | PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer(FATIMA) | unknown | Phase 2 | 160 | Hamdy A. AzimOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT04975451 | ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer | unknown | Phase 2 | 30 | Anqin ZhangOTHER | 1 | Jul 27, 2021 | clinicaltrials |
| NCT04452370 | Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer | unknown | Phase 2 | 100 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT04858997 | Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients | unknown | Phase 2 | 150 | Zhejiang Cancer HospitalOTHER | 1 | Jul 15, 2021 | clinicaltrials |
| NCT03580395 | Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer | unknown | Phase 2 / Phase 3 | 200 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT04941885 | Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer(Increase) | unknown | Phase 2 | 78 | Sun Yat-sen UniversityOTHER | 1 | Jul 2, 2021 | clinicaltrials |
| NCT04946227 | Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2') | unknown | Phase 2 | 52 | Yonsei UniversityOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT04936295 | Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation | unknown | Phase 2 | 61 | Sun Yat-sen UniversityOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04922008 | Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D) | unknown | Phase 2 | 356 | Fudan UniversityOTHER | 0 | Jun 10, 2021 | clinicaltrials |
| NCT04717531 | Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04913571 | Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study(TEMPLATE) | unknown | Phase 2 | 265 | Fudan UniversityOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04024800 | Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer(NSABP FB-14) | unknown | Phase 2 | 29 | NuGenerex Immuno-OncologyINDUSTRY | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04760431 | TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) | unknown | Phase 2 | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04907344 | Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | unknown | Phase 2 / Phase 3 | 420 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 28, 2021 | clinicaltrials |
| NCT02185352 | Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy in Breast Cancer With Brain Metastases(A-Plus) | unknown | Phase 2 | 120 | National Taiwan University HospitalOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04809779 | PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC(NeoPD1TNBC) | unknown | Phase 2 | 49 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 22, 2021 | clinicaltrials |
| NCT04170595 | Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection | unknown | Phase 1 / Phase 2 | 132 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04780347 | Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer | unknown | Phase 2 | 92 | Fudan UniversityOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT03698383 | Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer | unknown | Phase 2 | 15 | Korean Cancer Study GroupOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT04750382 | A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer | unknown | Phase 1 / Phase 2 | 31 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04736186 | Prevention and Treatment of Pyrrolitinib-associated Diarrhea | unknown | Phase 2 / Phase 3 | 470 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04705909 | Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer | unknown | Phase 2 / Phase 3 | 60 | Mansoura UniversityOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT04681911 | Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer | unknown | Phase 2 | 71 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT04034589 | Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer | unknown | Phase 2 | 46 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT04676997 | Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) | unknown | Phase 2 | 20 | Shandong Cancer Hospital and InstituteOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04659499 | Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer | unknown | Phase 2 | 261 | Peking Union Medical College HospitalOTHER | 0 | Dec 9, 2020 | clinicaltrials |
| NCT04639271 | Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis | unknown | Phase 2 | 100 | Shandong Cancer Hospital and InstituteOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT03144947 | Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients(IMMUN-HER) | unknown | Phase 2 | 65 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04580784 | Weekly Single Fraction Hypofractionated Adjuvant Radiotherapy for Early Stage Breast Cancer | unknown | Phase 2 | 20 | Mona SalemOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04571437 | Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)(B-001) | unknown | Phase 2 | 204 | Cairo UniversityOTHER | 1 | Oct 1, 2020 | clinicaltrials |
| NCT04559308 | The Effect of Metformin on Breast Cancer Patients | unknown | Phase 2 | 80 | Beni-Suef UniversityOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT04520386 | OMT-111 for Terminal Stage Solid Tumors | unknown | Phase 2 | 78 | MetiMedi PharmaceuticalsINDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04517292 | Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)(GEP) | unknown | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT04502680 | Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients(EMBRAVE-001) | unknown | Phase 2 | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 11, 2020 | clinicaltrials |
| NCT04499118 | AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer | unknown | Phase 2 | 100 | Sichuan Provincial People's HospitalOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT03504865 | Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo | unknown | Phase 2 | 100 | Georgetown UniversityOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT04488107 | Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c | unknown | Phase 1 / Phase 2 | 78 | Ahon Pharmaceutical Co., Ltd.OTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT04476641 | A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors(DC-CIK) | unknown | Phase 2 | 686 | Sun Yat-sen UniversityOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03044730 | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jul 13, 2020 | clinicaltrials |
| NCT03933319 | Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT04387630 | Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer. | unknown | Phase 2 / Phase 3 | 120 | Mansoura UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04073680 | A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Petra PharmaINDUSTRY | 0 | May 21, 2020 | clinicaltrials |
| NCT04158947 | A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone(HER2BAT) | unknown | Phase 2 | 130 | xuexin heOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT04247633 | High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx) | unknown | Phase 2 | 578 | Samsung Medical CenterOTHER | 1 | Apr 20, 2020 | clinicaltrials |
| NCT04302441 | A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy | unknown | Phase 2 | 550 | Fudan UniversityOTHER | 1 | Mar 10, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 13, 2021source: clinicaltrials